Janssen Announces U.S. FDA Approval of Novel TREMFYA (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis
![](https://pharmashots.com/wp-content/uploads/2019/02/PR-e1550232094431.png)
- Tell your healthcare provider right away if you have an infection or have symptoms of an?infection, including:
- fever, sweats, or chills
- muscle aches
- weight loss
- cough
- warm, red, or painful skin or sores on your body different from your psoriasis
- diarrhea or stomach pain
- shortness of breath
- blood in your phlegm (mucus)
- burning when you urinate or?urinating more often than normal
- have any of the conditions or symptoms listed in the section??What is the most?important information I should know about TREMFYA???
- have an infection that does not go away or that keeps coming back.
- have TB or have been in close contact with someone with TB.
- have recently received or are scheduled to receive an immunization (vaccine). You?should avoid receiving live vaccines during treatment with TREMFYA?.
- are pregnant or plan to become pregnant. It is not known if TREMFYA??can harm your?unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if TREMFYA??passes into your?breast milk.